Karman (NYSE:KRMN – Get Free Report) had its target price decreased by equities research analysts at Needham & Company LLC from $80.00 to $50.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC‘s price objective would indicate a potential upside of 54.33% from the company’s current price.
KRMN has been the topic of several other reports. KeyCorp reduced their price objective on Karman from $100.00 to $65.00 and set an “overweight” rating on the stock in a research note on Monday. Royal Bank Of Canada lowered their target price on Karman from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, October 28th. Citigroup boosted their target price on Karman from $76.00 to $78.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Piper Sandler restated an “overweight” rating and set a $60.00 price target (up from $59.00) on shares of Karman in a report on Friday. Finally, Guggenheim started coverage on Karman in a research report on Monday, September 14th. They issued a “buy” rating and a $63.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Karman presently has an average rating of “Moderate Buy” and an average price target of $73.00.
View Our Latest Research Report on Karman
Karman Price Performance
Shares of KRMN opened at $32.40 on Friday. Karman has a fifty-two week low of $29.34 and a fifty-two week high of $118.38. The firm’s 50 day moving average price is $35.97 and its 200 day moving average price is $62.81. The company has a market cap of $4.29 billion, a P/E ratio of 111.72 and a beta of 0.45. The company has a quick ratio of 3.40, a current ratio of 3.56 and a debt-to-equity ratio of 2.01.
Karman (NYSE:KRMN – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.16 by $0.03. The company had revenue of $201.62 million during the quarter. Karman had a net margin of 6.31% and a return on equity of 15.54%. The business’s quarterly revenue was up 65.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.10 EPS. On average, research analysts forecast that Karman will post 0.59 earnings per share for the current fiscal year.
Insider Activity
In other news, Director David Stinnett acquired 27,000 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were bought at an average price of $37.32 per share, with a total value of $1,007,640.00. Following the completion of the acquisition, the director owned 3,530,395 shares in the company, valued at $131,754,341.40. This trade represents a 0.77% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.77% of the company’s stock.
Institutional Trading of Karman
Several institutional investors and hedge funds have recently made changes to their positions in KRMN. Janney Montgomery Scott LLC grew its stake in Karman by 8.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,949 shares of the company’s stock worth $316,000 after buying an additional 297 shares during the last quarter. SBI Securities Co. Ltd. increased its position in Karman by 15.8% during the third quarter. SBI Securities Co. Ltd. now owns 2,526 shares of the company’s stock worth $82,000 after buying an additional 345 shares during the period. Parkside Financial Bank & Trust increased its position in Karman by 3,471.4% during the second quarter. Parkside Financial Bank & Trust now owns 500 shares of the company’s stock worth $25,000 after buying an additional 486 shares during the period. CX Institutional acquired a new position in Karman during the second quarter worth approximately $28,000. Finally, Hilltop National Bank lifted its stake in Karman by 87.8% in the second quarter. Hilltop National Bank now owns 1,258 shares of the company’s stock valued at $63,000 after buying an additional 588 shares during the last quarter.
Karman News Roundup
Here are the key news stories impacting Karman this week:
- Positive Sentiment: Q3 beat and strong growth: Karman earned $0.19 per share, above the $0.16 consensus and up from $0.10 a year earlier. Revenue reached $201.62 million, a 65.6% year-over-year increase. Karman Q3 earnings and revenues surpass estimates
- Positive Sentiment: 2026 outlook and backlog: The company expects $755 million–$760 million in 2026 revenue and reported a $1.7 billion backlog, supporting visibility into future business. Karman revenue outlook and backlog
- Positive Sentiment: Analyst support: Piper Sandler reaffirmed its Overweight rating and raised its price target to $60 from $59, implying substantial upside from the cited $32.40 price. Piper Sandler rating and price target update
- Neutral Sentiment: Trading context: The supplied snapshot shows shares well below their 50- and 200-day averages, while the stock’s high reported P/E may be a concern for investors. The articles provided do not identify a specific negative catalyst for the recent weakness.
Karman Company Profile
Karman Holdings Corp., doing business as Karman Space & Defense, is an aerospace and defense company that develops and manufactures mission-critical components, assemblies and structures. Its products are used in space-launch vehicles, missiles, hypersonic systems and other defense applications where performance, reliability and precision are essential.
The company’s capabilities include the production of composite and metallic structures, propulsion-related components, precision-machined parts and other highly engineered hardware.
Recommended Stories
- Five stocks we like better than Karman
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
Receive News & Ratings for Karman Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karman and related companies with MarketBeat.com's FREE daily email newsletter.
